Cargando…
Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection
(1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Follo...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675108/ https://www.ncbi.nlm.nih.gov/pubmed/38005952 http://dx.doi.org/10.3390/v15112276 |
_version_ | 1785149783014375424 |
---|---|
author | Edirisinghe, Hasindu S. Rajapaksa, Anushi E. Royce, Simon G. Sourial, Magdy Bischof, Robert J. Anderson, Jeremy Sarila, Gulcan Nguyen, Cattram D. Mulholland, Kim Do, Lien Anh Ha Licciardi, Paul V. |
author_facet | Edirisinghe, Hasindu S. Rajapaksa, Anushi E. Royce, Simon G. Sourial, Magdy Bischof, Robert J. Anderson, Jeremy Sarila, Gulcan Nguyen, Cattram D. Mulholland, Kim Do, Lien Anh Ha Licciardi, Paul V. |
author_sort | Edirisinghe, Hasindu S. |
collection | PubMed |
description | (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Following our previous study showing the successful lung deposition of aerosolised palivizumab in lambs, this current study evaluated the “proof-of-principle” effect of aerosolised palivizumab delivered as a therapeutic to neonatal lambs following RSV infection. (2) Methods: Neonatal lambs were intranasally inoculated with RSV-A2 on day 0 (day 3 post-birth) and treated with aerosolised palivizumab 3 days later (day 3 post-inoculation). Clinical symptoms, RSV viral load and inflammatory response were measured post-inoculation. (3) Results: Aerosolised therapeutic delivery of palivizumab did not reduce RSV viral loads in the nasopharynx nor the bronchoalveolar lavage fluid, but resulted in a modest reduction in inflammatory response at day 6 post-inoculation compared with untreated lambs. (4) Conclusions: This proof-of-principle study shows some evidence of aerosolised palivizumab reducing RSV inflammation, but further studies using optimized protocols are needed in order to validate these findings. |
format | Online Article Text |
id | pubmed-10675108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106751082023-11-19 Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection Edirisinghe, Hasindu S. Rajapaksa, Anushi E. Royce, Simon G. Sourial, Magdy Bischof, Robert J. Anderson, Jeremy Sarila, Gulcan Nguyen, Cattram D. Mulholland, Kim Do, Lien Anh Ha Licciardi, Paul V. Viruses Brief Report (1) Background: Palivizumab has been an approved preventative monoclonal antibody for respiratory syncytial virus (RSV) infection for over two decades. However, due to its high cost and requirement for multiple intramuscular injections, its use has been limited mostly to high-income countries. Following our previous study showing the successful lung deposition of aerosolised palivizumab in lambs, this current study evaluated the “proof-of-principle” effect of aerosolised palivizumab delivered as a therapeutic to neonatal lambs following RSV infection. (2) Methods: Neonatal lambs were intranasally inoculated with RSV-A2 on day 0 (day 3 post-birth) and treated with aerosolised palivizumab 3 days later (day 3 post-inoculation). Clinical symptoms, RSV viral load and inflammatory response were measured post-inoculation. (3) Results: Aerosolised therapeutic delivery of palivizumab did not reduce RSV viral loads in the nasopharynx nor the bronchoalveolar lavage fluid, but resulted in a modest reduction in inflammatory response at day 6 post-inoculation compared with untreated lambs. (4) Conclusions: This proof-of-principle study shows some evidence of aerosolised palivizumab reducing RSV inflammation, but further studies using optimized protocols are needed in order to validate these findings. MDPI 2023-11-19 /pmc/articles/PMC10675108/ /pubmed/38005952 http://dx.doi.org/10.3390/v15112276 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Edirisinghe, Hasindu S. Rajapaksa, Anushi E. Royce, Simon G. Sourial, Magdy Bischof, Robert J. Anderson, Jeremy Sarila, Gulcan Nguyen, Cattram D. Mulholland, Kim Do, Lien Anh Ha Licciardi, Paul V. Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection |
title | Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection |
title_full | Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection |
title_fullStr | Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection |
title_full_unstemmed | Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection |
title_short | Aerosol Delivery of Palivizumab in a Neonatal Lamb Model of Respiratory Syncytial Virus Infection |
title_sort | aerosol delivery of palivizumab in a neonatal lamb model of respiratory syncytial virus infection |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675108/ https://www.ncbi.nlm.nih.gov/pubmed/38005952 http://dx.doi.org/10.3390/v15112276 |
work_keys_str_mv | AT edirisinghehasindus aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT rajapaksaanushie aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT roycesimong aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT sourialmagdy aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT bischofrobertj aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT andersonjeremy aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT sarilagulcan aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT nguyencattramd aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT mulhollandkim aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT dolienanhha aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection AT licciardipaulv aerosoldeliveryofpalivizumabinaneonatallambmodelofrespiratorysyncytialvirusinfection |